VEGFR

Inhibitory Selectivity
Catalog No.Inhibitor Name VEGFR1VEGFR2VEGFR3Other
A10001Sorafenib Tosylate
**
Raf-1,B-Raf,B-Raf (V599E)
A10880Sunitinib Malate
*
Kit,FLT3,PDGFRβ
A10996Cabozantinib
***
****
***
c-Met,Kit,Axl
A10080Ponatinib
****
Abl,PDGFRα,FGFR1
A10103Axitinib
****
****
****
PDGFRβ,Kit,PDGFRα
A10998Foretinib
***
****
****
Met,Tie-2,RON
A10963Vandetanib
**
*
A10137Nintedanib
**
***
***
LCK,FLT3,FGFR2
A10250Regorafenib
***
****
*
RET,Raf-1,Kit
A11518Pazopanib HCl
***
**
*
FGFR,PDGFR,c-Kit
A10185Cediranib
***
****
****
c-Kit,PDGFRβ,FGFR1
A10703PD173074
*
FGFR1,c-Src
A11411Dovitinib
***
***
***
FLT3,c-Kit,FGFR1
A10025Linifanib
****
****
*
CSF-1R,FLT3,Kit
A10967Vatalanib 2HCl
*
**
*
PDGFRβ,c-Kit,c-Fms
A10773RAF265
**
B-Raf
A10101Tivozanib
**
***
**
EphB2,PDGFRα,PDGFRβ
A10608Motesanib Diphosphate
****
****
***
Kit,RET,PDGFR
A10340Lenvatinib
**
****
***
PDGFRβ,FGFR1,PDGFRα
A10953Orantinib
*
PDGFRβ,FGFR1
A10254Brivanib
*
**
FGFR1
A10587MGCD-265
****
****
****
Met,RON,Tie-2
A10043AEE788
*
*
*
EGFR,HER2/ErbB2,c-Abl
A10352ENMD-2076
*
**
FLT3,RET,Aurora A
A10679OSI-930
***
***
CSF-1R,LCK,C-Raf
A10248CYC116
**
Aurora A,Aurora B,FLT3
A10502Ki8751
****
c-Kit,PDGFRα,FGFR2
A10903Telatinib
***
****
c-Kit,PDGFRα
A11518Pazopanib
***
**
*
FGFR,PDGFR,c-Kit
A10504KRN 633
*
*
*
PDGFRα,c-Kit,BTK
A13377SAR131675
**
A10198Dovitinib Dilactic Acid
***
***
***
FLT3,c-Kit,FGFR1
A11407Apatinib
****
RET,c-Kit,c-Src
A10154BMS-794833
**
Met
A10162Brivanib Alaninate
*
**
FGFR1
A11396Golvatinib
**
c-Met
A11954ZM 323881 HCl
****
A11955ZM 306416
*
Src,Abl
A16342BFH772
****
A11558SU5402
**
FGFR1,PDGFRβ
A12437Semaxanib
*
A11244LY2874455
***
FGFR2,FGFR1,FGFR4
A13234SKLB1002
**
A14156AZD2932
***
PDGFRβ,Flt3,c-Kit
A10893Taxifolin (Dihydroquercetin)
A11772CP-547632
***
FGFR
A12693BAW2881 (NVP-BAW2881)
*
***
*
C-Raf-1,B-RAFV599E,c-Abl
A13465SKLB610
*
PDGFR, FGFR2
A13819TG 100801
****
***
FGFR1, Fyn, Src
A13820TG 100572
****
***
FGFR1, Fyn, Src
A14387ltiratinib (DCC2701)
***
MET, TIE2, TRK
A15073E-3810
***
**
***
FGFR-1, FGFR-2
A15287ZM323881
****
A15792BMS-817378
***
c-Met

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 50 of 78 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A15073

E-3810

VEGFR/FGFR Inhibitor
E-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VEGFR-1, VEGFR-2, VEGFR-3, FGFR-1 and FGFR-2, respectively.
A15760

SU10944

VEGFR Inhibitor
SU10944 is a small molecule kinase inhibitor of VEGFR that inhibits neovascularization and permeability, and is distributed to the eye upon systemic delivery.
A15287

ZM323881

VEGFR Inhibitor
ZM323881 is a potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) with IC50 value of 2 nM.
A15271

Vandetanib HCl

VEGFR inhibitor
Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
A15261

TG 100801 HCl

VEGFr2 inhibitor
TG 100801 is the prodrug of TG 100572 (HY-10184), TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
A15260

TG 100572 HCl

VEGFR2/Src kinase inhibitor
TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM for VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively.
A15250

SU14813 double bond Z

VEGFR Inhibitor
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).
A15182

N-Desethyl Sunitinib

VEGFR/PDGFRβ/KIT inhibitor
N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively).
A11772

CP-547632

VEGFR2 inhibitor
CP-547632 is a novel, potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor
A11496 SALE

Motesanib (AMG706)

VEGFR Inhibitor
Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors with IC?? values of 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3), 84 nM (PDGFR), and 8 nM (Kit).
A11557

SU14813

VEGFR Inhibitor
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3)
A11558 SALE

SU-5402

VVEGFR/FGFR/EGFR inhibitor‎
SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor (IC50 values are 0.02, 0.03, 0.51 and > 100 μM at VEGFR2, FGFR1, PDGFRβ and EGFR respectively).
A11581 SALE

Toceranib (PHA 291639, SU 11654)

c-Kit, PDGFR, VEGFR inhibitor
Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
A13111 SALE

R1530

Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor
R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
A13234

SKLB1002

VEGFR inhibitor
SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.
A12437 SALE

SU 5416 (Semaxinib)

VEGFR Inhibitor
SU 5416 is an inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET.
A11396 SALE

E-7050 (Golvatinib)

-
E7050 (also known as golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
A11244 SALE

LY 2874455

FGFR/VEGFR2 inhibitor
LY2874455 is a novel and potent FGFR/VEGFR Inhibitor.
A12027 SALE

(-)-Catechin gallate

-
(-)-Catechin gallate is an antioxidant constituent of green tea. At uM concentrations, inhibits VEGF-induced tyrosine phosphorylation.
A11955

ZM 306416 hydrochloride

VEGFR Inhibitor
ZM 306416 is a VEGF receptor tyrosine kinase inhibitor that inhibits KDR (IC50 = 100 nM) and Flt (IC50 = 2 uM) tyrosine kinases.
A11954

ZM 323881 hydrochloride

VEGFR Inhibitor
ZM 323881 is a potent and selective inhibitor of the kinase activity of the human vascular endothelial growth factor receptor 2 (VEGFR2/KDR).
A11737 SALE

Buflomedil HCl

VEGFR Antagonist
Buflomedil is a vasoactive agent used to treat peripheral vascular disease.
A11518 SALE

Pazopanib (GW-786034)

VEGFR inhibitor
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A11263

BMS-690514

VEGFR/EGFR Inhibitor
BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.
A13820

TG 100572

VEGFR2/Src inhibitor
TG 100572 is VEGFR2 and Src kinase inhibitor.
A13819

TG 100801

VEGFR2/Src inhibitor
TG 100801 is a VEGFR2 targeting prodrug currently in a clinical trial. The active form is TG100572.
A11472 SALE

Ki 20227

M-CSFR, CSF1R inhibitor
Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R).
A16237

EG00229

neuropilin-1/VEGF-A inhibitor
EG00229 is the first small molecule inhibitors of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM(125I-VEGF binding to PAE/NRP1 cells).
A16197

Nintedanib esylate

RTK inhibitor
Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
A12693 SALE

NVP-BAW2881

VEGFR inhibitor
NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation.
A13240

NVP-ACC789

VEGFR-2 inhibitor
NVP-ACC789 is an inhibitor of VEGFR-2 (FLK-1/KDR).
A14387

Altiratinib (DCC2701)

c-Met/VEGFR inhibitor
Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
A15792

BMS-817378

MET/VEGFR-2 inhibitor
BMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
A15272

Vandetanib trifluoroacetate

VEGFR/EGFR inhibitor
Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
A15263

Toceranib phosphate

-
Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
A15218

Regorafenib monohydrate

Tyrosine kinase inhibitor
Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
A13555

TAK-593

VEGFR/PDGFR inhibitor
TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity.
A13545

JI-101

VEGFR2/PDGFRβ/EphB4 inhibitor
JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities.
A14393

Fruquintinib

VEGFR inhibitor
Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities.
A14156

AZD 2932

mutil-targeted protein tyrosine kinase inhibitor
AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
A13465

SKLB610

VEGFR inhibitor
SKLB610 is a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
A13377

SAR131675

VEGFR3 Inhibitor
SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.
A16342

BFH772

VEGFR2 inhibitor
BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM.
A10504

KRN 633

VEGFR Inhibitor
KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ≥ 10 μM).
A10162

Brivanib alaninate (BMS-582664)

VEGFR inhibitor
Brivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
A10254 SALE

Brivanib (BMS-540215)

VEGFR-2 inhibitor
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
A10703 SALE

PD173074

FGFR1/VEGFR2 Inhibitor
PD173074 is a potent, cell permeable and ATP competitive inhibitor of FGFR and VEGFR.
A10587

MGCD-265 (Glesatinib)

c-Met inhibitor
MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.
A10043 SALE

AEE788

EGFR inhibitor
AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2.
A10137 SALE

Bibf1120 (Vargatef)

VEGFR inhibitor
BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.

Items 1 to 50 of 78 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction